Skip to main content

Table 4 Factors influencing KRAS testing in non-metastatic CRC patients

From: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer

  KRAS testing
N = 255/979 (26.1%)
Univariate analysis
P-Value
Multivariate analysis
Odds ratio 95% CI P-Value
Age (years)   0.0004    < 0.0001
  > 75 90 / 446 (20.2%)   1 Ref  
 60–75 123 / 382 (32.2%)   2.69 1.83–3.95  
  < 60 42 / 151 (27.8%)   2.26 1.34–3.81  
Sex   0.25    0.15
 Women 133 / 541 (24.6%)   1 Ref  
 Men 122 / 438 (27.9%)   0.77 0.55–1.09  
Site of the primary tumour   0.010    0.026
 Rectum 47 / 245 (19.2%)   1 Ref  
 Right colon 105 / 347 (30.3%)   1.95 1.20–3.16  
 Left colon 103 / 387 (26.6%)   1.47 0.92–2.35  
TNM stage   < 0.0001    < 0.0001
 I 21 / 219 (9.6%)   1 Ref  
 II 100 / 380 (26.3%)   5.24 2.98–9.21  
 III 134 / 380 (35.3%)   9.62 5.47–16.90  
Tumour grade (MD = 133)   0.0082a    
 Well 114 / 347 (32.8%)  
 Moderate 103 / 445 (23.2%)     
 Poor 17 / 54 (31.5%)     
Geographical area of primary treatment (MD = 2)   < 0.0001    < 0.0001
 Charente-Maritime 63 / 305 (20.7%)   1 Ref  
 Charente 13 / 173 (7.5%)   0.19 0.10–0.37  
 Deux-Sèvres 75 / 182 (41.2%)   3.74 2.35–5.95  
 Vienne 94 / 222 (42.3%)   3.24 1.95–5.39  
 Outside the region 10 / 95 (10.5%)   0.36 0.16–0.79  
Status of the center (MD = 2)   < 0.0001    < 0.0001
 Public Hospital 77 / 408 (18.9%)   1 Ref  
 Private hospital 149 / 429 (34.7%)   4.18 2.74–6.37  
 University hospital 29 / 140 (20.7%)   0.88 0.44–1.75  
  1. 95% CI 95% confidence interval, NA not available, MD missing data, Ref reference
  2. aNot retained in the final multivariate model